Spirovant Sciences

CompanyUnited States

Spirovant Sciences develops one asset, in phase 1 (SP-101 in cystic fibrosis). Mostly gene therapy acting on CFTR; based in the United States.

1
Asset
Furthest: Phase 1; 1
Trial: 0
Signals

Pipeline

1

SP-101
AAV gene therapy candidate designed to deliver CFTR for cystic fibrosis
Phase 1, Gene therapy, CFTR, cystic fibrosis

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials1
Similar companies6

Updated 7 Oct 2026 · 4 sources